Nonalcoholic fatty liver disease (NAFLD) is a complex spectrum of disorders ranging from simple benign steatosis to steatohepatitis (NASH) with fibrosis. NAFLD is increasingly common around the world, especially in Western nations.
There are still no FDA-approved therapeutics for this metabolic disease due to extremely high attrition in late-phase clinical trials, making the selection of appropriate preclinical research models critical for drug approval.
Taconic Biosciences is bringing together researchers across academia and industry to discuss translational NASH modeling, particularly as embodied in Westernized diet through enrichment with fat, cholesterol, and fructose. Join us for this virtual event on Thursday, August 25, 2022.
This engaging workshop will examine the translational value of different approaches, immune involvement in NASH, and applications of the preclinical models toward discovery and development of targeted therapies.
We encourage you to pose questions and share your own experiences during this interactive event. There will be a brief Q&A segment following each speaking session, and the workshop will conclude with a roundtable discussion.
Speakers:
Fred Beasley, PhD
Field Applications Scientist, Taconic Biosciences
Sridhar Radhakrishnan, PhD
Senior Scientist, Research Diets
Arion Kennedy, PhD
Assistant Professor, North Carolina State University
Harmeet Malhi, MBBS
Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Professor of Physiology, Professor of Medicine, Mayo Clinic Rochester
Michele Vacca, MD, PhD
Assistant Professor, Department of Medicine, Universita Degli Studi Di Bari Also Moro, and Member of the Litmus European Consortium